Brain Metastases of Papillary Thyroid Carcinoma with Horner’s Syndrome

Sung-Hoon Cho, Sang-Hyo Kim, Jung-Hwan Lee, Won-II Joo, Chung-Kee Chough, Hae-Kwan Park, Kyung-Jin Lee, Hyoung-Kyun Rha
Department of Neurosurgery, College of Medicine, The Catholic University of Korea, Yeouido St. Mary’s Hospital, Seoul, Korea

Received July 17, 2014
Revised September 11, 2014
Accepted October 7, 2014
Correspondence Won-II Joo
Department of Neurosurgery, College of Medicine, The Catholic University of Korea, Yeouido St. Mary’s Hospital, 10 63-ro, Yeongdeungpo-gu, Seoul 150-713, Korea
Tel: +82-2-3779-1187
Fax: +82-2-786-5809
E-mail: jwi@catholic.ac.kr

Brain Tumor Res Treat 2014;2(2):132-137 / pISSN 2288-2405 / eISSN 2288-2413
http://dx.doi.org/10.14791/btrt.2014.2.2.132

INTRODUCTION

Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and has relatively favorable prognosis. Blood-borne metastases of PTC are very rare among the thyroid malignancies. Moreover a case of blood-borne central nervous system metastasized PTC with only unilateral Horner’s syndrome, and without any abnormalities in laboratory or physical examinations has not been described before. A 53-year-old female patient had been managed in ophthalmologic clinic due to vague symptoms of right monocular blurred vision with eye dryness for 3 months, but showed no signs of improvement. So it was performed a magnetic resonance imaging and magnetic resonance angiography to evaluate the possibilities of cerebral lesion. And a left frontal mass was incidentally found, and the tumor turned out to be a PTC that had metastasized to brain, regional lymph node, cervical, thoracic spine, and lung. We describe a PTC with extraordinary initial symptoms that metastasized to an unusual site. We recommend that if a papillary thyroid tumor with unusual symptoms or at an advanced stage is found, further investigation should be performed for distant metastasis.

Key Words Papillary thyroid carcinoma; Metastases; Horner syndrome; Treatment.

CASE REPORT

A 53-year-old woman, with past history of only hysterectomy due to uterine myoma 4 years ago previously, visited our institute for incidental brain tumor. She had been visiting a local ophthalmologic clinic for 3 months, because of right eye monocular blurred vision and foreign body sensation. At the time she was diagnosed as xerophthalmia, but showed no sign of improvement despite the 3 months management. She complained of more aggravated symptoms of blurred vision and even showed hemi-facial numbness. The ophthalmologist recommended further evaluation of cerebral lesion. She visited a neurological clinic for brain imaging [magnetic resonance imaging (MRI), magnetic resonance angiography (MRA)] to evaluate the possibilities of cerebral infarction, transient ischemic attack or brain tumor. The brain MRI and MRA revealed a left frontal lobe cystic mass 1.7 × 2.2 × 2.1 cm in size. And it showed high signal intensity (SI) of T2 and low SI of T1 lesion with peripheral irregular enhancement. Although she visited our institute for visual disturbance and incidental cerebral mass, we thought that there was no connection between the
cerebral lesion and neurologic symptoms. So we thoroughly performed neurological exam again. We suggested right side Horner’s syndrome and diagnosis confirmation was done by the ophthalmologic department in our institute through the pharmacological test.

Further evaluation, positron-emitting tomography-computed tomography (PET-CT) (Fig. 1), chest CT, neck CT, neck MRI revealed that thyroid mass invading mediastinum, apex of lung, right common carotid artery, retropharyngeal space (Fig. 2), and even right internal jugular vein with tumor thrombus (Fig. 3). There was no definite goiter in physical exam, because of tumor growth in the caudal and dorsal direction.

Pre-operative thyroid function test was in normal range except for a high level of anti-thyroglobulin antibody (541.2 IU/mL, normal 0–70 IU/mL). There were no hormonal symptoms from thyroid or parathyroid gland dysfunction, and other laboratory results were also in normal range.

The fine needle aspiration biopsy was performed at right lobe of the thyroid gland. The pathologic diagnosis was PTC. To manage the primary lesion, total thyroidectomy with selective neck lymphatic dissection (III–IV) was performed in the otorhinolaryngologic department. Final pathologic diagnosis was PTC with tall cell variant and Hashimoto’s thyroiditis (Fig. 4). During the surgery, there were severe adhesions to surrounding tissue. To preserve major organs and structures, a small amount of tumor was remained. Her symptoms of mild ptosis, anhydrosis, and mild numbness of right hemi-facial area continued after the surgery.

After the primary lesion controls, brain surgery was performed 3 weeks later. We planned to use of navigator system for accurate tumor evacuation of the brain. In the navigator CT image, the tumor size had increased significantly to about 3.3×3×3.1 cm, but mainly from the cystic lesion. Craniotomy and gross total tumor removal was done by using of navigator system. The metastasized brain lesion was well marginated from normal parenchyme. The frozen biopsy result of metastasized tumor was adenoma-type malignancy, but final pathologic confirmation was same pathology of original site. Post-operative follow-up brain MRI image revealed complete removal of left frontal mass with two new small enhanced nodules on the right frontal and occipital lobe (Fig. 5). During the post-operative period, 99mTc pertechnetate bone scan (Fig. 6), and whole spine MRI were performed to evaluate distant metastases. It revealed additional metastases on 7th cervical, and 2nd thoracic vertebral body. We are planning whole brain radiotherapy with 30 Gy for remnant lesion first, then neck lesion radiotherapy and radioactive iodine ablation (131I) for distant metastases.

**DISCUSSION**

Malignant thyroid neoplasm includes papillary, follicular, medullary, anaplastic pathologic types. Among them, PTC is the most common type of 65–80% [6]. It has the most favorable prognosis, because they are a well differentiated type, usually juxta-nodal invasion and low incidence of vessel invasion or distant metastases [3]. It has 97.8% and 94.9% of 5-year and 10-year survival rate, respectively in non-metastatic PTC [7]. However, if it has metastasized to distant organs including lung or bone, their biological character can be aggressive. Blood-borne metastasis of PTC is very rare among the thyroid malignancies [8]. Some reports found the mean survival rate to be about 12 months, if there is the extremely rare case of brain metastases [1]. Our case also shows distant metastas-
Brain Metastases of Papillary Thyroid Carcinoma

The thyroid neoplasm is usually found because of symptoms of goiter, hoarseness, and sometimes through the regular screening test. In this case, however, there was no goiter or other symptoms. It shows only mild Horner’s syndrome, including subjective visual disturbance, xerophthalmia and mild ptosis, but no awareness of anhidrosis or miosis. Classic symptoms of Horner’s syndrome are the combination of ptosis, mi-

Fig. 2. The tumor growing toward mediastinum (red arrow) and retropharyngeal space and not which presenting goiter (A and D). The main mass located in deep cervical to lung apex lesion which encased major vessels and nerves, and deviated the trachea (B). Lung CT shows small nodular mass suspicious of metastasization from thyroid (C).

Fig. 3. Thyroid mass invaded into the vessel (arrow in A), with internal jugular venous thrombus (arrow in B) and cervical lymph node enlargement.
osis and hemifacial anhidrosis, and conjunctival injection of the eye or enophthalmos are often also present. This indicates a problem with the sympathetic nervous system related with facial lesion. Sympathetic nerve route associated with pupillary function can be divided into 3 lesions. The pre-ganglionic lesion is known as the most common origin site (21–67%) of Horner's syndrome, for example, compression or disruption by lung neoplasm. But thyroid mass lesion is an unusual cause

![Fig. 4. Pathologic images of thyroid low magnification (A) and high magnification (B), which show irregular nuclear membrane with enlarged, grooved nucleus. Papillary thyroid carcinoma (PTC) coexisted with Hashimoto’s thyroiditis (C). Metastasized cerebral tumor (D) showing same pathologic patterns as PTC. A and C: H&E, ×100. B and D: H&E, ×400.](image)

![Fig. 5. Brain pre-operative enhanced MRI image (A). There is a single cystic mass in left frontal lobe. But in the post-operative enhanced MRI image (B) shows total removal of left frontal mass, but additional enhanced small mass were also found in right frontal and occipital lobe during the interval of 4 weeks.](image)
Brain Metastases of Papillary Thyroid Carcinoma

Fig. 6. Bone scan with Tc-99m-pertechnetate shows a defect in the left parietal bone, as sequel of the recent craniotomy surgery. There is a metastatic skeletal hot uptake lesion of lower cervical spine.

of Horner’s syndrome (0.14–1.3%) [4,5]. Paradoxically, the most common cause of the Horner’s syndrome is due to malignancy including non-thyroidal lesion. But, in thyroidal lesion, benign thyroidal mass shows Horner’s syndrome more frequently (83%) than malignancy [9].

The thyroid mass presents Horner’s syndrome by involving the second or third order neuron of sympathetic pathway. If the mass is confirmed as malignancy, we should consider the possibility of tumor invasion of major vessels including carotid artery or jugular vein. Even though there is little evidence that malignant thyroid neoplasm with Horner’s syndrome always shows distant metastases, because of lack of collection, the possibilities should be considered. Generally, fluorodeoxyglucose (FDG)-PET is an excellent tool to evaluate the tumor metastases of the whole body. But when it comes to brain lesion, FDG-PET is not useful tool to detect brain metastases, because the brain metastases can often easily be obscured by the high FDG uptake of normal cortical gray matter [10]. However enhanced MRI is considered precise. In this case, the tumor lesion shows relatively cold spot and if the size had been smaller, it would have been obscured (Fig. 1).

The importance of physical and neurological examination is another point to emphasize. Especially, mismatched cases of brain imaging with neurologic symptoms should be re-considered. At first, there was no awareness of neck mass, and facial vague neurologic symptoms were the only clues in this case, and the brain metastatic lesion was found incidentally. If the classic evaluation of neurologic, physical examination was skipped, inappropriate and more risky study strategies would be selected or even led to misdiagnosis. For example, if there is a mass in cerebral eloquent area, attempts are usually made to get the tumor tissue through the biopsy or surgery, not taking into account the possibility of metastases. But knowing the primary site helped to find an easier access, diagnosis, and make the therapeutic strategy.

Although there is no definitely confirmed protocol for the treatment of brain metastases from thyroid cancer, surgery is generally considered to be the best therapeutic strategy for prolonged survival and regression of neurologic symptoms. After that, it is followed by radioiodine or external radiotherapy [1].

We decided treatment strategy by consulting with medical-oncologist, radio-oncologist, and otorhinolaryngologist. The plan was primary and metastasized lesion tumor removal first, followed by conventional radiotherapies. Regular metastases evaluation, additional boost radiotherapy schedules or doses were also discussed. PTC with metastasized to central nervous system was reported as poor prognosis. However, there is a report about a patient who survived for more than 10 years by a combined approach of total thyroidectomy, resection of brain metastatic lesion, radioactive iodine ($^{131}$I), suppressive therapy with L-throxine, whole brain body radiotherapy with
dose of 44 Gy, and gamma knife radiosurgery [1]. This case needed a tailored treatment because it is an extremely rare case with no standard therapy.

In conclusion, PTC is the most common type of thyroid malignancy. A thyroid tumor can be easily detectable at an early stage because of a noticeable and palpable mass or early other symptoms. Moreover PTC usually has a favorable outcome because of its relatively well differentiated pathology and indolent clinical course. However, if the tumor grows toward lung apex, mediastinum or retropharyngeal space, detection can be late. We describe an extremely rare case of vague early Horner’s syndrome symptoms but had cerebral metastasized PTC. In addition, we suggest that patients presenting with Horner’s syndrome should have a proper investigation performed to look for any revealed mass lesions, vascular lesions, or other treatable disorders.

Conflicts of Interest
The authors have no financial conflicts of interest.

REFERENCES
1. Miranda ER, Padrão EL, Silva BC, De Marco L, Sarquis MS. Papillary thyroid carcinoma with brain metastases: an unusual 10-year-survival case. Thyroid 2010;20:657-61.
2. McCaffrey TV, Bergstralh EJ, Hay ID. Locally invasive papillary thyroid carcinoma: 1940-1990. Head Neck 1994;16:165-72.
3. Gauden AJ, Gauden SJ. Multiple cerebral metastases as a primary presentation in papillary thyroid carcinoma. J Clin Neurosci 2010;17:379-80.
4. Harding JL, Sywak MS, Sidhu S, Delbridge LW. Horner’s syndrome in association with thyroid and parathyroid disease. ANZ J Surg 2004;74:442-5.
5. Broome JT, Gauger PG, Miller BS, Doherty GM. Anaplastic thyroid cancer manifesting as new-onset Horner syndrome. Endocr Pract 2009;15:563-6.
6. Tahmasebs FC, Farmer P, Powell SZ, et al. Brain metastases from papillary thyroid carcinomas. Virchows Arch 2013;462:473-80.
7. Mazzuferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 1977;56:171-96.
8. Yamagami Y, Tori M, Sakaki M, Ohtake S, Nakahara M, Nakao K. Thyroid carcinoma with extensive tumor thrombus in the atrium. Gen Thorac Cardiovasc Surg 2008;56:555-8.
9. Leuchter I, Becker M, Michel R, Dulgarev P. Horner’s syndrome and thyroid neoplasms. ORL J Otorhinolaryngol Relat Spec 2002;64:49-52.
10. Rini JN, Nguyen VT, Ben-Levi E, Naickh JJ, Yi Li J, Palestro CJ. Detection of papillary thyroid cancer brain metastasis with FDG-PET/CT. Clin Nucl Med 2010;35:357-9.